Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)450.37
  • Today's Change-0.86 / -0.19%
  • Shares traded1.51m
  • 1 Year change+26.94%
  • Beta0.3661
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments11,21810,7797,525
Total Receivables, Net1,5631,4421,137
Total Inventory739461353
Prepaid expenses622554546
Other current assets, total1.80----
Total current assets14,14413,2359,561
Property, plant & equipment, net1,4531,4561,424
Goodwill, net1,0881,0881,002
Intangibles, net840604400
Long term investments2,5969986
Note receivable - long term------
Other long term assets79742325
Total assets22,73018,15113,433
LIABILITIES
Accounts payable365304195
Accrued expenses2,5892,0521,501
Notes payable/short-term debt000
Current portion long-term debt/capital leases514147
Other current liabilities, total543345400
Total current liabilities3,5472,7422,142
Total long term debt376431510
Total debt427472557
Deferred income tax------
Minority interest------
Other liabilities, total1,2261,065681
Total liabilities5,1504,2383,333
SHAREHOLDERS EQUITY
Common stock2.602.602.50
Additional paid-in capital7,4507,3876,881
Retained earnings (accumulated deficit)10,1426,5233,201
Treasury stock - common------
Unrealized gain (loss)9.60(0.1)(0.5)
Other equity, total(24)0.9016
Total equity17,58013,91310,100
Total liabilities & shareholders' equity22,73018,15113,433
Total common shares outstanding258257254
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.